Abstract
The vascular system has an important function of supplying tissues with oxygen and nutrients and clearing waste products. Therefore, the microvasculature must be sufficiently permeable to allow the free, bidirectional passage of small molecules and gases and, to a lesser extent, of plasma proteins. It is well recognized that vascular endothelial growth factor (VEGF) can increase vascular permeability, thus playing important roles in variety of disorders, including diabetic retinopathy, nephrotic syndrome, brain edema, acute respiratory distress syndrome, and sepsis-associated hypotension. However, how vascular permeability is controlled by anti-permeable factors is not fully understood. We have recently found that pigment epithelium-derived factor (PEDF), a 50kD glycoprotein, inhibits retinal, renal and brain hyperpermeability by counteracting the biological actions of VEGF. In this review, we discuss about the pathophysiological role of PEDF in vascular permeability, especially focusing on retinal- renal disorders.
Keywords: Diabetic retinopathy, hyperpermeability, nephrotic syndrome, PEDF, VEGF
Current Molecular Medicine
Title: Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Volume: 10 Issue: 3
Author(s): S. Ueda, S.-I. Yamagishi and S. Okuda
Affiliation:
Keywords: Diabetic retinopathy, hyperpermeability, nephrotic syndrome, PEDF, VEGF
Abstract: The vascular system has an important function of supplying tissues with oxygen and nutrients and clearing waste products. Therefore, the microvasculature must be sufficiently permeable to allow the free, bidirectional passage of small molecules and gases and, to a lesser extent, of plasma proteins. It is well recognized that vascular endothelial growth factor (VEGF) can increase vascular permeability, thus playing important roles in variety of disorders, including diabetic retinopathy, nephrotic syndrome, brain edema, acute respiratory distress syndrome, and sepsis-associated hypotension. However, how vascular permeability is controlled by anti-permeable factors is not fully understood. We have recently found that pigment epithelium-derived factor (PEDF), a 50kD glycoprotein, inhibits retinal, renal and brain hyperpermeability by counteracting the biological actions of VEGF. In this review, we discuss about the pathophysiological role of PEDF in vascular permeability, especially focusing on retinal- renal disorders.
Export Options
About this article
Cite this article as:
Ueda S., Yamagishi S.-I. and Okuda S., Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders, Current Molecular Medicine 2010; 10 (3) . https://dx.doi.org/10.2174/156652410791065291
DOI https://dx.doi.org/10.2174/156652410791065291 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dopamine: Agonists and Neurodegenerative Disorders
Current Drug Targets Status Epilepticus: An Overview
Current Drug Metabolism Synthesis of 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-(substituted phenyl)pyrimidin-2-ol Analogues as Anti-Inflammatory and Analgesic Agents
Letters in Drug Design & Discovery Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews Purinergic Signalling and Endothelium
Current Vascular Pharmacology New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Ezogabine: Development and Role in the Management of Epileptic Seizures
Mini-Reviews in Medicinal Chemistry The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design The “Parkinsonian Heart”: From Novel Vistas to Advanced Therapeutic Approaches in Parkinsons Disease
Current Medicinal Chemistry COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Current Medicinal Chemistry Corticosteroids for the Inflammatory Response to Cardiopulmonary Bypass: An Update
Current Pharmaceutical Design The Use of Echocardiography in the Critically Ill; The Role of FADE (Fast Assessment Diagnostic Echocardiography) Training
Current Cardiology Reviews Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Insulin Neuritis and Diabetic Cachectic Neuropathy: A Review
Current Diabetes Reviews Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic: Inhibition of the Renin-Angiotensin-Aldosterone System: How to Obtain This (Executive Guest Editors: Aldo Pende and Fabrizio Montecucco )]
Current Pharmaceutical Design Depression and Vascular Disease: Conceptual Issues, Relationships and Clinical Implications
Vascular Disease Prevention (Discontinued)